A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumoursGabriel Mak, Hendrik‐Tobias Arkenau, Kurt R. Auger et al.|British Journal of Cancer|2019Cited by 103
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumoursAlastair Greystoke, William P. Steward, Sarah P. Blagden et al.|Annals of Oncology|2006Cited by 24
517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumoursNatalie Cook, Ruth Plummer, Sarah P. Blagden et al.|Annals of Oncology|2021Cited by 10
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.Hendrik‐Tobias Arkenau, Li Yan, Anas Gazzah et al.|Journal of Clinical Oncology|2015Cited by 7
Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on Day 1 (T and C) and Day 8 (T) every three weeks in patients (pts) with advanced solid tumorsSarah P. Blagden, W.P. Steward, Adam G. Thomas et al.|Journal of Clinical Oncology|2005Cited by 3